Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Author
Publication date
2024-11ISSN
1542-3565
Abstract
Background & Aims: The impact of patient sex on the presentation of inflammatory bowel disease (IBD) has been poorly evaluated. Our aims were to assess potential disparities in IBD phenotype and progression between sexes.
Methods: We performed an observational multicenter study that included patients with Crohn's disease (CD) or ulcerative colitis from the Spanish Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes genéticos y Ambientales registry. Data extraction was conducted in July 2021.
Results: A total of 51,595 patients with IBD were included, 52% were males and 25,947 had CD. The median follow-up period after diagnosis was 9 years in males and 10 years in females. In CD, female sex was an independent risk factor for medium disease onset (age, 17–40 y) (relative risk ratio, 1.45; 95% CI, 1.31–1.62), later disease onset (age, >40 y) (relative risk ratio, 1.55; 95% CI, 1.38–1.73), exclusive colonic involvement (odds ratio, 1.24; 95% CI, 1.14–1.34), inflammatory behavior (odds ratio, 1.14; 95% CI, 1.07–1.21), and extraintestinal manifestations (odds ratio, 1.48; 95% CI, 1.38–1.59). However, female sex was a protective factor for upper gastrointestinal involvement (odds ratio, 0.84; 95% CI, 0.79–0.90), penetrating behavior (odds ratio, 0.76; 95% CI, 0.70–0.82), perianal disease (odds ratio, 0.77; 95% CI, 0.71–0.82), and complications (odds ratio, 0.73; 95% CI, 0.66–0.80). In ulcerative colitis, female sex was an independent risk factor for extraintestinal manifestations (odds ratio, 1.48; 95% CI, 1.26–1.61). However, female sex was an independent protective factor for disease onset from age 40 onward (relative risk ratio, 0.76; 95% CI, 0.66–0.87), left-sided colonic involvement (relative risk ratio, 0.72; 95% CI, 0.67–0.78), extensive colonic involvement (relative risk ratio, 0.59; 95% CI, 0.55–0.64), and abdominal surgery (odds ratio, 0.78; 95% CI, 0.69–0.88).
Conclusions: There is sexual dimorphism in IBD. The patient's sex should be taken into account in the clinical management of the disease.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
61 - Medical sciences
Keywords
Pages
Desconocido
Publisher
Elsevier
Is part of
Clinical Gastroenterology and Hepatology
Recommended citation
Gargallo, C. J.; Ricart Gomez, E.; Iglesias, E. [et. al.]. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA. Clinical Gastroenterology and Hepatology, 2024, Volume 22, Issue 11, pp. 2280-2290. Disponible en: <https://www.cghjournal.org/article/S1542-3565(24)00487-7/fulltext>. Fecha de acceso: 6 May 2026. DOI: 10.1016/j.cgh.2024.05.013
Note
Acknowledgments: The authors are sincerely grateful to Erika Alfambra for administrative support. The authors also are grateful to Alberto Cebollada for statistical support. The Supplementary Appendix list the affiliations of the Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes genéticos y Ambientales: Nationwide study on genetic and environmental determinants of inflammatory bowel disease-Grupo Español de trabajo en Enfermedad de Crohn y Colitis Ulcerosa investigators. Funding: The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) of Grupo Español de trabajo en Enfermedad de Crohn y Colitis Ulcerosa is supported by Takeda, Pfizer, Galápagos, AbbVie, and Biogen. None of them had access to the clinical information or were involved in the present analysis.
This item appears in the following Collection(s)
- Ciències de la Salut [1041]
Rights
© 2024 by the AGA Institute

